Editor's Note

Setting Benchmarks in India's Burgeoning Realm of Pharma

Pharma CDMOs in India have brought forth a strategic shift in the ever-important drug development process for pharma companies. Today, Indian CDMOs are evolving beyond the traditional model to stay relevant with the changing market dynamics leveraging the proven CDMO 2.0 model. These players today are not just mere contract developers and manufacturers, but rather have evolved into more strategic, tech-agnostic partners offering a one-stop solution.

Similarly, the India oncology clinical trials market generated USD 571.8 million in 2025 and is projected to reach USD 1,337.5...  >>More